Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators studied the effect of CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.
Observational studies have shown that chronic total coronary occlusion percutaneous intervention (CTO-PCI) improves angina, left ventricular ejection fraction (LVEF), and survival. None of these studies aimed to assess the benefits in populations with heart failure with reduced ejection fraction (HFrEF). The investigators studied the effect of CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.
Using cardiac magnetic resonance (CMR), the investigators studied 29 patients with HFrEF and evidence of viability and/or ischemia in the territory supplied by an occluded vessel who were successfully treated with CTO-PCI. Non-CTO PCI was also performed in patients with multi-vessel disease, . Imaging parameters, clinical status, and brain natriuretic peptide (BNP) levels were evaluated before and six months after CTO-PCI.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Successful CTO PCI | Active Comparator | Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI) |
|
| Unsuccessful CTO PCI | No Intervention | Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| chronic total coronary occlusion percutaneous intervention | Procedure | Percutaneous intervention of chronic total coronary occlusion with stent implantation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Left ventricular ejection fraction (%) | Evaluate changes in left ventricular function by cardiac magnetic resonance imaging 6 months after CTO PCI | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| NYHA functional class (I-V) | Evaluate changes in NYHA functional class 6 months after CTO PCI | 6 months |
| Myocardial ischemia | Evaluate changes in number of segments with induced ischemia by cardiac magnetic resonance imaging 6 months after CTO PCI |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27814739 | Derived | Cardona M, Martin V, Prat-Gonzalez S, Ortiz JT, Perea RJ, de Caralt TM, Masotti M, Perez-Villa F, Sabate M. Benefits of chronic total coronary occlusion percutaneous intervention in patients with heart failure and reduced ejection fraction: insights from a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2016 Nov 5;18(1):78. doi: 10.1186/s12968-016-0287-5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| Brain Natriuretic Peptide (pg/ml) | Evaluate changes in brain natriuretic peptide 6 months after CTO PCI | 6 months |
| Incidence of in-hospital CTO PCI major adverse events | Safety evaluation of CTO PCI in patients with HFrEF (periprocedural mortality, periprocedural STEMI or need for urgent myocardial revascularization surgery) | 6 months |